Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Diabetes Metab Syndr Obes ; 15: 3669-3678, 2022.
Article in English | MEDLINE | ID: mdl-36465990

ABSTRACT

Background: Bariatric and metabolic surgery (BMS) is an effective treatment for obesity and its complications, but its effect on pregnancy outcomes is inconclusive. The present study aimed to investigate women's pregnancy status and outcomes as well as the impact of pregnancy intervals after BMS. Methods: The menstrual cycle and fertility status of women who underwent BMS in our centre between July 2010 and January 2021 were retrospectively analyzed and followed up until one-year post-delivery. The pregnancy outcomes after BMS were observed, including changes in weight, pregnancy interval, pregnancy complications, weight and health status of the newborn (premature birth, admission to neonatology, or deformity). Results: We identified 31 women who were successfully conceived after BMS. There were statistical differences in weight and menstrual status before and post-operation (P < 0.05), and 77.97% of them had remission or recovery of obesity-related comorbidities. Eighteen patients delivered successfully after BMS, but there were still 12 cases of spontaneous abortion and 1 case of induced abortion. The abortion rate in pregnancy intervals less than 2 years was higher than those ≥2 years (P = 0.045). Of the women who delivered successfully, 5 had pregnancy-specific complications, including gestational diabetes mellitus and hypertensive disorder of pregnancy. However, the growth and development of the newborn are normal since the birth follow-up. Conclusion: The present results suggest that the abortion rate in pregnancy intervals less than 2 years was higher than those ≥2 years. It is recommended that postoperative patients avoid pregnancy until their weight is stable to reduce the risk of adverse pregnancy outcomes.

2.
Obes Surg ; 32(3): 819-828, 2022 03.
Article in English | MEDLINE | ID: mdl-35088249

ABSTRACT

BACKGROUND: Postoperative nausea and vomiting (PONV) is common side effect after gastrointestinal surgery. It causses discomfort, increase risk of incision disruption, bleeding and airway blockage. This study aimed to investigate the incidence and severity of PONV and determine whether preoperative reflux or regurgitation symptoms influence PONV in patients undergoing bariatric surgery. METHODS: Patients with obesity underwent laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) in our center between January 2016 and December 2018 were divided into PONV and NoPONV group and analyzed retrospectively. PONV and postoperative pain visual analogue scale (VAS) were analyzed after surgery. A 1:1 propensity score matching (PSM) method was performed, and multivariable logistic regression analyses were used to identify predictors for PONV. RESULTS: There were 483 patients enrolled, with a mean age of 30.19 ± 9.96 years, and 134 pairs of matched patients were selected from PONV group and NoPONV group after PSM. PONV occurred in 288 (59.6%) patients after bariatric surgery (77.4% after LSG vs 21.5% after LRYGB, p < 0.001). In PONV group, 210 (72.9%) were female, preoperative reflux or regurgitation symptoms were 128 (33.6%). Multivariable analysis found that preoperative reflux or regurgitation symptoms were independent risk factors for PONV after LSG, with an OR of 2.78 (95% CI: 1.12-6.93, p = 0.028). CONCLUSIONS: Incidence of PONV after bariatric surgery is high. For the first time, this study valued preoperative reflux or regurgitation symptoms as risk factors that may promote PONV after bariatric surgery. Patients with preoperative symptoms undergoing LSG have a higher risk of PONV, so these patients should be carefully evaluated for the feasibility of LSG before surgery.


Subject(s)
Bariatric Surgery , Gastric Bypass , Gastroesophageal Reflux , Laparoscopy , Obesity, Morbid , Adult , Bariatric Surgery/adverse effects , Female , Gastrectomy/adverse effects , Gastrectomy/methods , Gastric Bypass/methods , Gastroesophageal Reflux/epidemiology , Humans , Laparoscopy/adverse effects , Laparoscopy/methods , Male , Obesity, Morbid/surgery , Postoperative Complications/epidemiology , Postoperative Nausea and Vomiting/epidemiology , Postoperative Nausea and Vomiting/etiology , Propensity Score , Retrospective Studies , Young Adult
3.
J Metab Bariatr Surg ; 9(1): 1-6, 2020 Jun.
Article in English | MEDLINE | ID: mdl-36686896

ABSTRACT

Postprandial hyperinsulinemic hypoglycemia (PHH) is one of the serious complications after bariatric surgery, it can lead life-threatening neuroglycopenic symptoms, such as seizures, disorientation, impairment of version and loss of consciousness without any premonitory. The presentation, prevalence, diagnosis, pathology and treatment are reviewed in this summary.

4.
Asia Pac J Clin Nutr ; 27(3): 540-545, 2018.
Article in English | MEDLINE | ID: mdl-29737800

ABSTRACT

BACKGROUND AND OBJECTIVES: Nutrition and inflammation play a crucial role in the development of cancer. The prognostic value of the prognostic nutritional index (PNI) has been confirmed in some types of human cancers. This study analyzed the prognostic significance of the preoperative PNI in patients with stage III gastric cancer after curative surgery. METHODS AND STUDY DESIGN: In this retrospective study, we enrolled 274 patients who underwent curative operation for stage III gastric cancer. The correlation between the preoperative PNI and overall survival (OS) was analyzed using Kaplan-Meier curves and multivariate Cox regression analyses. RESULTS: The patients with a high PNI had a significantly higher median OS than did those with a low PNI (46.8 months vs 24.1 months, p=0.01). In the subgroup analysis, the survival benefit of the PNI was limited to the patients with poorly differentiated gastric cancer (high PNI, 46.8 months; low PNI, 21.8 months, p=0.004) and was not observed in those with well and moderately differentiated cancer (high PNI, 30.3 months; low PNI, 26.7 months, p=0.30). In the multivariate analysis, the PNI was an independent prognostic factor for OS. CONCLUSIONS: The PNI can be used as an independent prognostic biomarker for operable advanced gastric cancer.


Subject(s)
Nutrition Assessment , Nutritional Status , Stomach Neoplasms/surgery , Cohort Studies , Gastrectomy , Humans , Middle Aged , Retrospective Studies
5.
Biochem Biophys Res Commun ; 436(2): 300-5, 2013 Jun 28.
Article in English | MEDLINE | ID: mdl-23743199

ABSTRACT

Nerve growth factor (NGF) has been reported to be involved in male reproductive physiology. However, few reports have described the activity of NGF during Leydig cell development. The objective of the present study was to examine the role of NGF during stem-Leydig-cell (SLC) regeneration. We investigated the effects of NGF on Leydig-cell (LC) regeneration by measuring mRNA levels in the adult rat testis after ethane dimethanesulfonate (EDS) treatment. Furthermore, we used the established organ culture model of rat seminiferous tubules to examine the regulation of NGF during SLC proliferation and differentiation using EdU staining, real-time PCR and western blotting. Progenitor Leydig cells (PLCs) and immature Leydig cells (ILCs) were also used to investigate the effects of NGF on LCs at different developmental stages. NGF mRNA levels changed significantly during Leydig-cell regeneration in vivo. In vitro, NGF significantly promoted the proliferation of stem Leydig cells and also induced steroidogenic enzyme gene expression and 3ß-HSD protein expression. The data from PLCs and ILCs showed that NGF could increase Cyclin D1 and Hsd 17b3 mRNA levels in PLCs and Cyclin D1 mRNA levels in ILCs. These results indicate that NGF may play an important role during LC regeneration by regulating the proliferation and differentiation of LCs at different developmental stages, from SLCs to PLCs and from PLCs to ILCs. The discovery of this effect of NGF on Leydig cells will provide useful information for developing new potential therapies for PADAM (Partial Androgen Deficiency in the Aging Male).


Subject(s)
Cell Differentiation/genetics , Cell Proliferation , Leydig Cells/metabolism , Nerve Growth Factor/genetics , Regeneration/genetics , Stem Cells/metabolism , Animals , Blotting, Western , Cell Differentiation/drug effects , Cells, Cultured , Cyclin D1/genetics , Cyclin D1/metabolism , Gene Expression/drug effects , Leydig Cells/cytology , Leydig Cells/drug effects , Male , Mesylates/pharmacology , Multienzyme Complexes/genetics , Multienzyme Complexes/metabolism , Nerve Growth Factor/metabolism , Nerve Growth Factor/pharmacology , Organ Culture Techniques , Phosphoproteins/genetics , Phosphoproteins/metabolism , Progesterone Reductase/genetics , Progesterone Reductase/metabolism , Rats , Rats, Sprague-Dawley , Regeneration/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Seminiferous Tubules/cytology , Seminiferous Tubules/drug effects , Seminiferous Tubules/metabolism , Stem Cells/cytology , Stem Cells/drug effects , Steroid Isomerases/genetics , Steroid Isomerases/metabolism , Testolactone/analogs & derivatives , Testolactone/blood , Testolactone/metabolism , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...